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Measles, mumps, and rubella vaccination and bowel
problems or developmental regression in children with
autism: population study
Brent Taylor, Elizabeth Miller, Raghu Lingam, Nick Andrews, Andrea Simmons, Julia Stowe
Abstract
Objectives To investigate whether measles, mumps,
and rubella (MMR) vaccination is associated with
bowel problems and developmental regression in
children with autism, looking for evidence of a “new
variant” form of autism.
Design Population study with case note review linked
to independently recorded vaccine data.
Setting Five health districts in north east London.
Participants 278 children with core autism and 195
with atypical autism, mainly identified from
computerised disability registers and born between
1979 and 1998.
Main outcome measures Recorded bowel problems
lasting at least three months, age of reported
regression of the child’s development where it was a
feature, and relation of these to MMR vaccination.
Results The proportion of children with
developmental regression (25% overall) or bowel
symptoms (17%) did not change significantly (P value
for trend 0.50 and 0.47, respectively) during the 20
years from 1979, a period which included the
introduction of MMR vaccination in October 1988.
No significant difference was found in rates of bowel
problems or regression in children who received the
MMR vaccine before their parents became concerned
about their development (where MMR might have
caused or triggered the autism with regression or
bowel problem), compared with those who received it
only after such concern and those who had not
received the MMR vaccine. A possible association
between non›specific bowel problems and regression
in children with autism was seen but this was
unrelated to MMR vaccination.
Conclusions These findings provide no support for
an MMR associated “new variant” form of autism with
developmental regression and bowel problems, and
further evidence against involvement of MMR vaccine
in the initiation of autism.
Introduction
The suggestion that the measles, mumps, and rubella
(MMR) vaccine causes or triggers autism centres on the
putative existence of “new variant” autism where devel›
opmental regression is reported to follow shortly after
MMR vaccination, typically accompanied by bowel
symptoms.1 Epidemiological studies designed to inves›
tigate such a causal association have found no
correspondence between temporal trends in MMR
uptake and the incidence of autism, nor any evidence
of clustering of onset of behavioural disturbance,
including regression, shortly after vaccination.2–6 How›
ever, it is now postulated that the onset of MMR
induced “regressive autism” with “autistic enterocolitis”
may occur after a prolonged induction interval and, in
addition, requires the presence of cofactors such as an
intercurrent infection, receipt of antibiotics, a history of
atopy, a strong family history of autoimmune disease,
or MMR or rubella immunisation of the mother
shortly before, during, or after pregnancy.7 This modi›
fied hypothesis could thereby explain the negative
findings of the epidemiological studies. Whatever the
postulated induction interval or trends in incidence of
autism, the present hypothesis requires that the
proportion of autistic children with regression and
bowel symptoms be higher in children given MMR
vaccine before parents became concerned about their
child’s development and that the pattern of bowel
problems and regression in autism should have
changed after MMR was introduced.
We have published epidemiological evidence that
showed no causal association between MMR vaccina›
tion and autism.2 3 We repeated that survey in late 2000
and early 2001 after an interval of two and a half years
in five of the original eight study districts to examine
further the relation between MMR vaccine and the
onset of autism, particularly autism associated with
regression, and to collect information on bowel
problems in children with autism.
Methods
We identified children with childhood and atypical
autism born between 1979 and 1998 from computer›
ised health registers of children with disabilities in the
community and from special school and child psychia›
try records, using the same methods and classifications
as in our earlier study.2 3 We abstracted information
from the clinical notes then linked the information to
independent computerised vaccination records (the
Definitions
Childhood autism
Children with symptoms before the age of 3 years that
meet the necessary criteria* under each section of the
diagnostic triad for autism: communication difficulties,
problems with social interaction, and behaviour
problems such as stereotyped repetitions
Atypical autism
Cases with many of the features of childhood autism
but not quite meeting the required criteria for that
diagnosis, or with atypical features such as onset of
symptoms after age 3 years (also known as pervasive
developmental disorder not otherwise specified)
Developmental regression
A documented deterioration in any aspect of
development or reported loss of skills, however
transient
*ICD›10 (international classification of diseases, 10th
revision) and DSMIV (Diagnostic and Statistical Manual of
Mental Disorders, 4th ed)
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regional interactive child health system, or TotalCare),
which were inputted about the time of vaccination. We
recorded bowel problems where the history docu›
mented they had lasted at least three months. We also
recorded the age at onset of concern about the child’s
development. We recorded regression if there was
documented deterioration in any aspect of a child’s
development or reported loss of skills.
Statistical analysis
We used single and multivariable logistic regression
models to investigate in detail the relation between
exposure to MMR vaccine in relation to onset of
autism and the presence of bowel symptoms or
regression, with adjustment for potential confounding
factors—namely sex, year of birth, district, age at paren›
tal concern, and type of autism. We show only single
variable results because adjustment for potential
confounders did not substantially affect the results.
Results
We identified 278 children with childhood autism and
195 with atypical autism. Of these 473 children, 81
(17%) were reported to have associated bowel
problems: constipation (42 children), constipation and
diarrhoea (7), diarrhoea (19), food allergy (7),
non›specific colitis with ileal›lymphoid›nodular hyper›
plasia (2), and other (4). The proportion with bowel
symptoms was similar in those with childhood and
with atypical autism: 49 of 278 (18%) and 32 of 195
(16%), respectively (P = 0.73). Regression of the child’s
development was reported by parents in 118 (25%) of
the 469 children where developmental information
was recorded. Apparent loss of speech or language
skills or change in behaviour were the major forms of
regression identified. The proportion with regression
was similar in those with childhood and with atypical
autism: 43 of 191 (23%) and 75 of 278 (27%),
respectively (P = 0.27). No significant trends by year of
birth were found in the percentages of children with
autism who had bowel symptoms (odds ratio 0.98, 95%
confidence interval 0.93 to 1.04; P = 0.50) or with
regression (0.98, 0.93 to 1.03; P = 0.47) during the 20
years from 1979, a period during which the MMR vac›
cine was introduced (October 1988) in the United
Kingdom (figure). The proportion with regression or
bowel problems by year of birth showed a similar pat›
tern for childhood and atypical cases (data not shown).
The single and multivariable logistic regression
models confirmed no association between MMR vacci›
nation and regression or bowel symptoms. The table
compares children who received the vaccine before
their parents became concerned about their develop›
ment with those who received it only after concern,
and those who never received it. No significant
difference was found between the proportions in either
the single or multivariable models (bowel problems
P = 0.48; regression P = 0.83). These analyses were
repeated for the 28 cases with bowel problems most
likely to reflect the putative disorder “autistic
enterocolitis”—that is, food allergy, diarrhoea without
constipation, and non›specific colitis with ileal›
lymphoid›nodular hyperplasia. The results showed no
evidence of an association with MMR vaccination
(P = 0.57), nor a change by year of birth in the
proportion with these symptoms (odds ratio 0.98, 0.89
to 1.07; P = 0.58).
Although neither bowel problems nor regression
was related to MMR vaccination, bowel problems were
reported more frequently in children with regression
than in those without, 31 of 118 (26%) and 49 of 351
(14%), respectively (P = 0.002). This relationship
between bowel problems and regression did not
significantly vary by type of bowel problem (P = 0.35).
For the 31 children with both bowel symptoms and
regression, there was also no association with MMR
vaccination (P = 0.20) and no association with year of
birth (1.01, 0.92 to 1.11; P = 0.79).
Discussion
Evidence was lacking to support a “new variant” form
of autism, where MMR vaccination is associated with
developmental regression and bowel problems. We
found no change in the proportion of autistic children
with bowel problems or developmental regression over
a 20 year period from 1979, a period when MMR vac›
cination was introduced in the United Kingdom
(October 1988). We did find an association between
bowel problems and regression in our population, but
there was no relation between these factors and MMR
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Numbers (percentages) of children with autism and bowel problems or developmental
regression who had received MMR vaccine before or after their parents became
concerned about their development or who had never received vaccine
Vaccine before
parental concern
(n=257)
Vaccine after parental
concern (n=129)
No vaccine
(n=57)
Overall
(n=443)*
Bowel problems 50 (19) 19 (15) 9 (16) 78 (18)
Regression 68 (26) 33 (26) 17 (30) 118 (27)
*Age at parental concern only available for 443 of 473 children.
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vaccination. The occurrence of the two symptoms
together might reflect particular dietary problems
leading to constipation in some children with autism
who have regression, or other unknown influences on
factors associated with the development and progress
of this pattern of autism. Children with autism who
have speech loss have more severe learning difficulties
several years later than those without such regression.8
Bowel symptoms have been reported in an
epidemiological study of 96 children with autism, born
between 1992 and 1995 in Stafford, England.9 All but
one of these children had been immunised with MMR
vaccine. The study also compared the age at onset of
regression and first parental concern with two earlier
clinical samples of children, one studied before and the
other after the introduction of MMR vaccine (but with
no record in those two samples as to whether the indi›
vidual children had been immunised). No change in
the average age of regression or parental concern was
noted in the three groups. Bowel problems were
recorded only for the most recent sample and, unlike
our findings and possibly reflecting smaller numbers,
the study found no association between bowel
problems and regression. The much larger numbers in
our epidemiological study enabled us to look for
changes in a population of children with autism over a
20 year period, as well as to allow for possible
confounders and, with our complete vaccine linkage,
directly to compare regression and bowel symptoms in
children who were or were not vaccinated with MMR.
Bowel problems, particularly constipation, occur in
many children with various kinds of neurodevelopmen›
tal disorder. The percentage we found in our autistic
population (17% overall) is closely similar to the 19%
previously reported.9 Those authors supplemented and
validated information from the clinical records with
questionnaire information directly from the families.
That percentages in the two studies are similar provides
validation of our method of data collection. Although
there have been further reports10 11 of a specific bowel
disorder associated with autism from the group who
originally described the possible syndrome,1 there is
little support for the postulated mechanism involving
MMR vaccination.12 Many children with autism have
unusual diets, often associated with constipation, which
might lead to non›specific abnormalities of the bowel.
The enteric nervous system is likely to be abnormal in
children with autism for whatever the genetic reason for
autism turns out to be.12
The frequency of regression in autism is uncertain.13
One study reviewed published evidence and reported
rates varying between 22% and 50%.9 Many children
with autism have infantile speech, which usually stops in
such children, as in developmentally normal children,
before age 18 months. In normal children more
communicative speech usually overlaps. The failure of
this normal communicative speech to develop in
children who have autism, coinciding with the disap›
pearance of infantile vocalisations, may be overinter›
preted as regression of speech and language. Our figure
of 25% with developmental regression, although in
accord with other studies, is likely to include many such
children and is likely to be an overestimate. Regression
was found in only 16% of the contemporary group in
the Stafford study, using carefully validated data from a
standardised interview for diagnosing autism.9 14 This
16% compared with 18% in the clinical group who were
born between 1954 and 1979 (before MMR vaccina›
tion).9 These figures support our finding that rates of
regression in autism are unchanged over many years.
Our study has the strengths and weaknesses of data
based on case notes. Data were not recorded systemati›
cally, and there was variability in the level of detail.
However, information was available from a variety of
sources, including notes from health visitors about the
children’s early life, and notes from hospitals, child
development centres, and other community records
such as from schools. Thus a serial record was available
for each child, including letters from other centres such
as those specialising in autism or paediatric gastroen›
terology. We assessed the accuracy and consistency of
our data collection by duplicating the process
independently in 40 cases; interobserver agreement on
key variables was over 98%. The review of case notes
was carried out independently of the MMR history,
which came from a different, independent source
(computerised records from the time of vaccination).
A review of each record showed that in 13 children
the history given by the parents had changed after the
extensive publicity about MMR vaccine and autism.
Before the publicity the parents often reported concerns
early in their child’s life, usually before their first
birthday; the current history for the same children
recorded symptoms as developing only after MMR vac›
cination, in some cases shortly after. This bias associated
with changes in the history given by the parents necessi›
tates particular care when interpreting the planned self›
controlled case series analysis of the present dataset.2 3
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What is already known on this topic
A “new variant” form of autism has been hypothesised, associated with
developmental regression and bowel problems and caused or triggered
by the MMR vaccination
This postulated association along with media attention has had a major
adverse effect on public confidence in the vaccine
Although population studies have shown no association between
autism and MMR vaccine it has been further postulated that various
environmental or genetic cofactors are required for the effect
What this study adds
The proportion of children with autism who had developmental
regression or bowel problems has not changed over the 20 years from
1979
Neither developmental regression nor bowel problems in children with
autism was associated with MMR vaccination
No evidence was found for a “new variant” form of autism
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Socioeconomic differences in Swedish children and
adolescents injured in road traffic incidents:
cross sectional study
Lucie Laflamme, Karin Engström
Traffic related injuries are among the most common
causes of death in childhood and in youth.1 Young
people belonging to a low social class and living in
deprived socioeconomic areas are consistently at
greater risk than others.2 3 The extent to which
socioeconomic differences in risks from traffic injury
vary during childhood and adolescence deserves
consideration.4 5 We examined socioeconomic pattern›
ing in Swedish children and adolescents injured in
road traffic incidents, considering four categories of
road users.
Methods and results
We created a dataset of about 2.2 million children and
adolescents (aged 0›19 years) living in Sweden at some
time during 1990›4 by linking records from 13 Swedish
national registers. We established their sex and year of
birth by linking the Swedish population register to the
national censuses of 1985 or 1990 or to the medical
register of births, according to the person’s age.
Subjects were divided into four age groups and
allocated to one of four household socioeconomic sta›
tuses (table) based on that of the parent with the high›
est status. The Swedish socioeconomic status is a
measure of class, based on occupation and the average
level of education required for any particular
occupation. Status was attributed to the parents by Sta›
tistics Sweden in the Swedish population and housing
census of 1990.
We linked the data on sex, year of birth, and
socioeconomic status of the young people to five annual
national hospital discharge registers (1990›4) and to the
national causes of death register. The latter has about
4.5% of cases lacking information on either E›code
(cause of injury) or personal identification number of
the injured person. We considered fatal and non›fatal
injuries, based on the assumption that the number of
lethal injuries did not vary greatly between socioeco›
nomic groups.2 We avoided double counting by exclud›
ing from the outpatient register any person with the
same diagnosis in both registers within two months.
Four diagnostic categories were considered accord›
ing to ICD›9 (international classification of diseases,
ninth revision): pedestrian injuries, bicycle related inju›
ries, injuries as motor vehicle passenger, and injuries as
motor vehicle driver (table) (13 772 road traffic injuries
in total).
We performed a series of regressions by category of
injury diagnosis for each age group to calculate the
relative risk of injury according to socioeconomic
status. Children of households classified as high or
intermediate level salaried employees were used as the
reference group. We tested for—but did not find—a
possible modification effect of sex of child on socioeco›
nomic patterning; therefore boys and girls were
considered together. However, the model used for the
later regressions did include the variable for sex of
child to test whether boys were at a much greater risk
than girls, regardless of socioeconomic status. All
analyses were performed using SAS version 6.12.
The relative risks of being injured in a traffic related
incident were generally—but not consistently—greater
for boys than for girls (table). Socioeconomic
differences are negligible in the early years of life (0›4
years) but for all other age groups the relative risks are
appreciably higher for children of unskilled workers
than for those of high or intermediate level salaried
employees. Relative risks are particularly pronounced
at 10›14 years of age for non›pedestrians, and at 15›19
years for drivers and riders of motorised vehicles.
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